<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02037347</url>
  </required_header>
  <id_info>
    <org_study_id>0901004673</org_study_id>
    <secondary_id>020901</secondary_id>
    <nct_id>NCT02037347</nct_id>
  </id_info>
  <brief_title>Study to Evaluate the Use of Palifermin to Treat Toxic Epidermal Necrolysis</brief_title>
  <official_title>Palifermin Treatment of Toxic Epidermal Necrolysis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Brett King</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Swedish Orphan Biovitrum</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Yale University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To test the ability of palifermin (a recombinant human keratinocyte growth factor) to
      decrease mucocutaneous injury and to promote epithelial repair in Toxic Epidermal Necrolysis
      and Stevens-Johnson Syndrome-Toxic Epidermal Necrolysis Overlap, diseases in which there is
      extensive sloughing of the skin and mucosa, including that of the eyes, gastrointestinal
      tract, respiratory and genitourinary systems.
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Low enrollment numbers precluded completion of the study during a reasonable amount of time.
  </why_stopped>
  <start_date>October 2010</start_date>
  <completion_date type="Actual">December 2014</completion_date>
  <primary_completion_date type="Actual">December 2014</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Time-to-cutaneous Re-epithelialization</measure>
    <time_frame>The number of days between the start of palifermin administration and complete re-epithelialization of skin up to 14 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time-to-mucosal Re-epithelialization</measure>
    <time_frame>The number of days between the start of palifermin administration and complete re-epithelialization of oral mucosa up to 14 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time-to-cessation of Epidermal Necrosis</measure>
    <time_frame>The number of days between the start of palifermin administration and cessation of further epidermal necrosis up to 14 days</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">1</enrollment>
  <condition>Toxic Epidermal Necrolysis</condition>
  <condition>Stevens-Johnson Syndrome</condition>
  <arm_group>
    <arm_group_label>Palifermin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Palifermin 60 micrograms/kg/day IV for 3 consecutive days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Palifermin</intervention_name>
    <arm_group_label>Palifermin</arm_group_label>
    <other_name>Kepivance</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Skin biopsy in early disease showing apoptotic keratinocytes in the epidermis and in
             more advanced disease necrosis of the entire epidermis

          -  Epidermal detachment or erythematous to purpuric macules involving more than 10% of
             body surface area in addition to involvement of the oropharynx; there may be further
             involvement of other mucosal surfaces, ie. conjunctivae, gastrointestinal tract,
             respiratory and genitourinary epithelia

          -  Age of 18 years old or older

          -  The patient is expected to survive longer than 48 hours

        Exclusion Criteria:

          -  Skin detachment above 90% of the body surface area

          -  Skin detachment has not progressed during the previous 48 hours

          -  A positive serum pregnancy test

          -  Age &lt; 18 years old

          -  Known hematologic or solid organ malignancy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Bridgeport Hospital</name>
      <address>
        <city>Bridgeport</city>
        <state>Connecticut</state>
        <zip>06610</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Yale-New Haven Hospital</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06510</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 13, 2014</study_first_submitted>
  <study_first_submitted_qc>January 13, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 15, 2014</study_first_posted>
  <results_first_submitted>October 6, 2016</results_first_submitted>
  <results_first_submitted_qc>October 6, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">November 30, 2016</results_first_posted>
  <last_update_submitted>October 6, 2016</last_update_submitted>
  <last_update_submitted_qc>October 6, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 30, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Yale University</investigator_affiliation>
    <investigator_full_name>Brett King</investigator_full_name>
    <investigator_title>Assistant Professor of Dermatology</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stevens-Johnson Syndrome</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Palifermin</title>
          <description>Palifermin 60 micrograms/kg/day IV for 3 consecutive days</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>73-year-old male.</population>
      <group_list>
        <group group_id="B1">
          <title>Palifermin</title>
          <description>Palifermin 60 micrograms/kg/day IV for 3 consecutive days</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="1"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age, Customized</title>
          <units>years</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Age</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Time-to-cutaneous Re-epithelialization</title>
        <time_frame>The number of days between the start of palifermin administration and complete re-epithelialization of skin up to 14 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Palifermin</title>
            <description>Palifermin 60 micrograms/kg/day IV for 3 consecutive days</description>
          </group>
        </group_list>
        <measure>
          <title>Time-to-cutaneous Re-epithelialization</title>
          <units>days</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time-to-mucosal Re-epithelialization</title>
        <time_frame>The number of days between the start of palifermin administration and complete re-epithelialization of oral mucosa up to 14 days</time_frame>
        <population>Adverse event experienced by participant precluded measuring this outcome.</population>
        <group_list>
          <group group_id="O1">
            <title>Palifermin</title>
            <description>Palifermin 60 micrograms/kg/day IV for 3 consecutive days</description>
          </group>
        </group_list>
        <measure>
          <title>Time-to-mucosal Re-epithelialization</title>
          <population>Adverse event experienced by participant precluded measuring this outcome.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time-to-cessation of Epidermal Necrosis</title>
        <time_frame>The number of days between the start of palifermin administration and cessation of further epidermal necrosis up to 14 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Palifermin</title>
            <description>Palifermin 60 micrograms/kg/day IV for 3 consecutive days</description>
          </group>
        </group_list>
        <measure>
          <title>Time-to-cessation of Epidermal Necrosis</title>
          <units>days</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Palifermin</title>
          <description>Palifermin 60 micrograms/kg/day IV for 3 consecutive days</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>ischemic necrosis</sub_title>
                <description>ischemic necrosis of the small bowel</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Brett King MD</name_or_title>
      <organization>Yale University</organization>
      <phone>203-785-4092</phone>
      <email>brett.king@yale.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

